Tyrosine kinase 2 – Surveillant of tumours and bona fide oncogene

Cytokine

Volumn 89, Issue , 2017, Pages 209-218

  Leitner, Nicole R ^a   Witalisz Siepracka, Agnieszka ^a   Strobl, Birgit ^a   Müller, Mathias ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Cytokine signalling; Hallmarks of cancer; JAK STAT pathway; Non receptor tyrosine kinases

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 1; ESTROGEN RECEPTOR ALPHA; GLYCOPROTEIN GP 130; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR 2; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 13 RECEPTOR ALPHA1; PROTEIN TYROSINE KINASE; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTOME; TYROSINE KINASE 2; UNCLASSIFIED DRUG; PROTEIN KINASE TYK2; TUMOR PROTEIN; TYK2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; AUTOINFLAMMATION; AUTOPHAGY; CANCER EPIDEMIOLOGY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ENERGY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME STABILITY; ENZYME STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GAIN OF FUNCTION MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; INTRACELLULAR SIGNALING; LYMPH NODE METASTASIS; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS; TUMOR INVASION; TUMOR REJECTION; TYK2 GENE; ANIMAL; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; LEUKEMIA; MOUSE; MUTATION; SIGNAL TRANSDUCTION;

ANIMALS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LEUKEMIA; MICE; MUTATION; NEOPLASM PROTEINS; ONCOGENES; SIGNAL TRANSDUCTION; TYK2 KINASE;

EID: 84949507084     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.10.015     Document Type: Review

References (202)

1. [1] Darnell, J.E. Jr., Kerr, I.M., Stark, G.R., Jak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994), 1415–1421.
2. [2] Stark, G.R., Darnell, J.E. Jr., The JAK–STAT pathway at twenty. Immunity 36 (2012), 503–514.
3. [3] Velazquez, L., Fellous, M., Stark, G.R., Pellegrini, S., A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70 (1992), 313–322.
4. [4] Macchi, P., Villa, A., Giliani, S., Sacco, M.G., Frattini, A., Porta, F., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377 (1995), 65–68.
5. [5] Muller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366 (1993), 129–135.
6. [6] Russell, S.M., Tayebi, N., Nakajima, H., Riedy, M.C., Roberts, J.L., Aman, M.J., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270 (1995), 797–800.
7. [7] Watling, D., Guschin, D., Muller, M., Silvennoinen, O., Witthuhn, B.A., Quelle, F.W., et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 366 (1993), 166–170.
8. [8] Levy, D.E., Darnell, J.E. Jr., Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002), 651–662.
9. [9] O'Shea, J.J., Plenge, R., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36 (2012), 542–550.
10. [10] Agaisse, H., Perrimon, N., The roles of JAK/STAT signaling in Drosophila immune responses. Immunol. Rev. 198 (2004), 72–82.
11. [11] Liongue, C., O'Sullivan, L.A., Trengove, M.C., Ward, A.C., Evolution of JAK–STAT pathway components: mechanisms and role in immune system development. PLoS ONE, 7, 2012, e32777.
12. [12] Sobhkhez, M., Hansen, T., Iliev, D.B., Skjesol, A., Jorgensen, J.B., The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function. Dev. Comp. Immunol. 41 (2013), 553–563.
13. [13] Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., Pfeffer, K., Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93 (1998), 397–409.
14. [14] Parganas, E., Wang, D., Stravopodis, D., Topham, D.J., Marine, J.C., Teglund, S., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93 (1998), 385–395.
15. [15] Rodig, S.J., Meraz, M.A., White, J.M., Lampe, P.A., Riley, J.K., Arthur, C.D., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93 (1998), 373–383.
16. [16] Nosaka, T., van Deursen, J.M., Tripp, R.A., Thierfelder, W.E., Witthuhn, B.A., McMickle, A.P., et al. Defective lymphoid development in mice lacking Jak3. Science 270 (1995), 800–802.
17. [17] Park, S.Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3 (1995), 771–782.
18. [18] Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13 (2000), 549–560.
19. [19] Sheehan, K.C., Lai, K.S., Dunn, G.P., Bruce, A.T., Diamond, M.S., Heutel, J.D., et al. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26 (2006), 804–819.
20. [20] Shimoda, K., Kato, K., Aoki, K., Matsuda, T., Miyamoto, A., Shibamori, M., et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13 (2000), 561–571.
21. [21] Shaw, M.H., Boyartchuk, V., Wong, S., Karaghiosoff, M., Ragimbeau, J., Pellegrini, S., et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. USA 100 (2003), 11594–11599.
22. [22] Izumi, K., Mine, K., Inoue, Y., Teshima, M., Ogawa, S., Kai, Y., et al. Reduced Tyk2 gene expression in beta-cells due to natural mutation determines susceptibility to virus-induced diabetes. Nat. Commun., 6, 2015, 6748.
23. [23] Vielnascher, R.M., Hainzl, E., Leitner, N.R., Rammerstorfer, M., Popp, D., Witalisz, A., et al. Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance. Transgenic Res. 23 (2014), 519–529.
24. [24] Ahmed, C.M., Johnson, H.M., The role of a non-canonical JAK–STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis: an example of Occam's Broom?. JAKSTAT, 2, 2013, e26227.
25. [25] Strobl, B., Stoiber, D., Sexl, V., Mueller, M., Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. (Landmark Ed) 16 (2011), 3214–3232.
26. [26] Uze, G., Schreiber, G., Piehler, J., Pellegrini, S., The receptor of the type I interferon family. Curr. Top. Microbiol. Immunol. 316 (2007), 71–95.
27. [27] Keil, E., Finkenstadt, D., Wufka, C., Trilling, M., Liebfried, P., Strobl, B., et al. Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation. Blood 123 (2014), 520–529.
28. [28] Prchal-Murphy, M., Semper, C., Lassnig, C., Wallner, B., Gausterer, C., Teppner-Klymiuk, I., et al. TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS ONE, 7, 2012, e39141.
29. [29] Kilic, S.S., Hacimustafaoglu, M., Boisson-Dupuis, S., Kreins, A.Y., Grant, A.V., Abel, L., et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J. Pediatr. 160 (2012), 1055–1057.
30. [30] Ma, C.S., Wong, N., Rao, G., Avery, D.T., Torpy, J., Hambridge, T., et al. Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies. J. Allergy Clin. Immunol. 136 (2015), 993–1006.
31. [31] Minegishi, Y., Saito, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 (2006), 745–755.
32. [32] Kreins, A.Y., Ciancanelli, M.J., Okada, S., Kong, X.F., Ramirez-Alejo, N., Kilic, S.S., et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 212 (2015), 1641–1662.
33. [33] Ubel, C., Mousset, S., Trufa, D., Sirbu, H., Finotto, S., Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology, 2, 2013, e22840.
34. [34] O'Shea, J.J., Holland, S.M., Staudt, L.M., JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368 (2013), 161–170.
35. [35] Vainchenker, W., Constantinescu, S.N., JAK/STAT signaling in hematological malignancies. Oncogene 32 (2013), 2601–2613.
36. [36] Firmbach-Kraft, I., Byers, M., Shows, T., Dalla-Favera, R., Krolewski, J.J., Tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5 (1990), 1329–1336.
37. [37] Krolewski, J.J., Lee, R., Eddy, R., Shows, T.B., Dalla-Favera, R., Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene 5 (1990), 277–282.
38. [38] Wilks, A.F., Harpur, A.G., Kurban, R.R., Ralph, S.J., Zurcher, G., Ziemiecki, A., Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell Biol. 11 (1991), 2057–2065.
39. [39] Babon, J.J., Lucet, I.S., Murphy, J.M., Nicola, N.A., Varghese, L.N., The molecular regulation of Janus kinase (JAK) activation. Biochem. J. 462 (2014), 1–13.
40. [40] Funakoshi-Tago, M., Pelletier, S., Moritake, H., Parganas, E., Ihle, J.N., Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol. Cell Biol. 28 (2008), 1792–1801.
41. [41] Zhou, Y.J., Chen, M., Cusack, N.A., Kimmel, L.H., Magnuson, K.S., Boyd, J.G., et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell 8 (2001), 959–969.
42. [42] Wallweber, H.J., Tam, C., Franke, Y., Starovasnik, M.A., Lupardus, P.J., Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2. Nat. Struct. Mol. Biol. 21 (2014), 443–448.
43. [43] Murphy, J.M., Zhang, Q., Young, S.N., Reese, M.L., Bailey, F.P., Eyers, P.A., et al. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem. J. 457 (2014), 323–334.
44. [44] Silvennoinen, O., Ungureanu, D., Niranjan, Y., Hammaren, H., Bandaranayake, R., Hubbard, S.R., New insights into the structure and function of the pseudokinase domain in JAK2. Biochem. Soc. Trans. 41 (2013), 1002–1007.
45. [45] Lupardus, P.J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A.R., Eigenbrot, C., Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. USA 111 (2014), 8025–8030.
46. [46] Min, X., Ungureanu, D., Maxwell, S., Hammaren, H., Thibault, S., Hillert, E.K., et al. Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2). J. Biol. Chem., 2015, 10.1074/jbc.M115.672048 pii: jbc.M115.672048 (Epub ahead of print).
47. [47] Bai, Y., Li, J., Fang, B., Edwards, A., Zhang, G., Bui, M., et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res. 72 (2012), 2501–2511.
48. [48] Daub, H., Olsen, J.V., Bairlein, M., Gnad, F., Oppermann, F.S., Korner, R., et al. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol. Cell 31 (2008), 438–448.
49. [49] Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007), 1190–1203.
50. [50] Schreiber, T.B., Mausbacher, N., Keri, G., Cox, J., Daub, H., An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol. Cell Proteomics 9 (2010), 1047–1062.
51. [51] Shiromizu, T., Adachi, J., Watanabe, S., Murakami, T., Kuga, T., Muraoka, S., et al. Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J. Proteome Res. 12 (2013), 2414–2421.
52. [52] Zheng, H., Hu, P., Quinn, D.F., Wang, Y.K., Phosphotyrosine proteomic study of interferon alpha signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. Mol. Cell Proteomics 4 (2005), 721–730.
53. [53] Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O.N., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18 (2011), 971–976.
54. [54] Kim, W., Bennett, E.J., Huttlin, E.L., Guo, A., Li, J., Possemato, A., et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell 44 (2011), 325–340.
55. [55] Sedek, M., Strous, G.J., SUMOylation is a regulator of the translocation of Jak2 between nucleus and cytosol. Biochem. J. 453 (2013), 231–239.
56. [56] Siewert, E., Muller-Esterl, W., Starr, R., Heinrich, P.C., Schaper, F., Different protein turnover of interleukin-6-type cytokine signalling components. Eur. J. Biochem. 265 (1999), 251–257.
57. [57] Caldas-Lopes, E., Cerchietti, L., Ahn, J.H., Clement, C.C., Robles, A.I., Rodina, A., et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. USA 106 (2009), 8368–8373.
58. [58] Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K.D., Karras, G.I., et al. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 150 (2012), 987–1001.
59. [59] Akahane, K., Sanda, T., Mansour, M.R., Radimerski, T., DeAngelo, D.J., Weinstock, D.M., et al. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia, 2015, 10.1038/leu.2015.222 (Epub ahead of print).
60. [60] Liang, J., Tsui, V., Van Abbema, A., Bao, L., Barrett, K., Beresini, M., et al. Lead identification of novel and selective TYK2 inhibitors. Eur. J. Med. Chem. 67 (2013), 175–187.
61. [61] Argiriadi, M.A., Goedken, E.R., Banach, D., Borhani, D.W., Burchat, A., Dixon, R.W., et al. Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Struct. Biol., 12, 2012, 22.
62. [62] Lupardus, P.J., Skiniotis, G., Rice, A.J., Thomas, C., Fischer, S., Walz, T., et al. Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Ralpha cytokine receptor complex, and the receptor-Jak1 holocomplex. Structure 19 (2011), 45–55.
63. [63] Brooks, A.J., Dai, W., O'Mara, M.L., Abankwa, D., Chhabra, Y., Pelekanos, R.A., et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science, 344, 2014, 1249783.
64. [64] Olsen, J.V., Mann, M., Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol. Cell Proteomics 12 (2013), 3444–3452.
65. [65] Doudna, J.A., Charpentier, E., Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 346, 2014, 1258096.
66. [66] Pestka, S., Krause, C.D., Walter, M.R., Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202 (2004), 8–32.
67. [67] Schreiber, G., Piehler, J., The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 36 (2015), 139–149.
68. [68] Rutz, S., Wang, X., Ouyang, W., The IL-20 subfamily of cytokines – from host defence to tissue homeostasis. Nat. Rev. Immunol. 14 (2014), 783–795.
69. [69] Ouyang, W., Rutz, S., Crellin, N.K., Valdez, P.A., Hymowitz, S.G., Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29 (2011), 71–109.
70. [70] Vignali, D.A., Kuchroo, V.K., IL-12 family cytokines: immunological playmakers. Nat. Immunol. 13 (2012), 722–728.
71. [71] McCormick, S.M., Heller, N.M., Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 75 (2015), 38–50.
72. [72] Bhattacharjee, A., Shukla, M., Yakubenko, V.P., Mulya, A., Kundu, S., Cathcart, M.K., IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radic. Biol. Med. 54 (2013), 1–16.
73. [73] Garbers, C., Hermanns, H.M., Schaper, F., Muller-Newen, G., Grotzinger, J., Rose-John, S., et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 23 (2012), 85–97.
74. [74] Hermanns, H.M., Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 26 (2015), 545–558.
75. [75] Hainzl, E., Stockinger, S., Rauch, I., Heider, S., Berry, D., Lassnig, C., et al. Intestinal epithelial cell tyrosine kinase 2 transduces IL-22 signals to protect from acute colitis. J. Immunol., 2015, 10.4049/jimmunol.1402565 pii: 1402565 (Epub ahead of print).
76. [76] Ishizaki, M., Akimoto, T., Muromoto, R., Yokoyama, M., Ohshiro, Y., Sekine, Y., et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J. Immunol. 187 (2011), 181–189.
77. [77] Ishizaki, M., Muromoto, R., Akimoto, T., Sekine, Y., Kon, S., Diwan, M., et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int. Immunol. 26 (2014), 257–267.
78. [78] Smith, C.L., Arvedson, T.L., Cooke, K.S., Dickmann, L.J., Forte, C., Li, H., et al. IL-22 regulates iron availability in vivo through the induction of hepcidin. J. Immunol. 191 (2013), 1845–1855.
79. [79] Works, M.G., Yin, F., Yin, C.C., Yiu, Y., Shew, K., Tran, T.T., et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J. Immunol. 193 (2014), 3278–3287.
80. [80] Bosmann, M., Strobl, B., Kichler, N., Rigler, D., Grailer, J.J., Pache, F., et al. Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27. J. Leukoc. Biol. 96 (2014), 123–131.
81. [81] Yoshimura, A., Naka, T., Kubo, M., SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7 (2007), 454–465.
82. [82] Alexander, W.S., Suppressors of cytokine signalling (SOCS) in the immune system. Nat. Rev. Immunol. 2 (2002), 410–416.
83. [83] Bourdonnay, E., Zaslona, Z., Penke, L.R., Speth, J.M., Schneider, D.J., Przybranowski, S., et al. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J. Exp. Med. 212 (2015), 729–742.
84. [84] Linossi, E.M., Nicholson, S.E., Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins. Immunol. Rev. 266 (2015), 123–133.
85. [85] Babon, J.J., Kershaw, N.J., Murphy, J.M., Varghese, L.N., Laktyushin, A., Young, S.N., et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36 (2012), 239–250.
86. [86] Narazaki, M., Fujimoto, M., Matsumoto, T., Morita, Y., Saito, H., Kajita, T., et al. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc. Natl. Acad. Sci. USA 95 (1998), 13130–13134.
87. [87] Piganis, R.A., De Weerd, N.A., Gould, J.A., Schindler, C.W., Mansell, A., Nicholson, S.E., et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J. Biol. Chem. 286 (2011), 33811–33818.
88. [88] Sakamoto, H., Yasukawa, H., Masuhara, M., Tanimura, S., Sasaki, A., Yuge, K., et al. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 92 (1998), 1668–1676.
89. [89] Zeng, B., Li, H., Liu, Y., Zhang, Z., Zhang, Y., Yang, R., Tumor-induced suppressor of cytokine signaling 3 inhibits toll-like receptor 3 signaling in dendritic cells via binding to tyrosine kinase 2. Cancer Res. 68 (2008), 5397–5404.
90. [90] David, M., Chen, H.E., Goelz, S., Larner, A.C., Neel, B.G., Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell Biol. 15 (1995), 7050–7058.
91. [91] Yetter, A., Uddin, S., Krolewski, J.J., Jiao, H., Yi, T., Platanias, L.C., Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J. Biol. Chem. 270 (1995), 18179–18182.
92. [92] Myers, M.P., Andersen, J.N., Cheng, A., Tremblay, M.L., Horvath, C.M., Parisien, J.P., et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 276 (2001), 47771–47774.
93. [93] Zhang, X., Han, X., Tang, Y., Wu, Y., Qu, B., Shen, N., MiR-744 enhances type I interferon signaling pathway by targeting PTP1B in primary human renal mesangial cells. Sci. Rep., 5, 2015, 12987.
94. [94] Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G., et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409 (2001), 349–354.
95. [95] Woellner, C., Schaffer, A.A., Puck, J.M., Renner, E.D., Knebel, C., Holland, S.M., et al. The hyper IgE syndrome and mutations in TYK2. Immunity, 26, 2007, 535 author reply 6.
96. [96] Mogensen, T.H., Primary immunodeficiencies with elevated IgE. Int. Rev. Immunol., 2015, 1–18, 10.3109/08830185.2015.1027820 (Epub ahead of print).
97. [97] Tao, J.H., Zou, Y.F., Feng, X.L., Li, J., Wang, F., Pan, F.M., et al. Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases. Mol. Biol. Rep. 38 (2011), 4663–4672.
98. [98] Cunninghame Graham, D.S., Morris, D.L., Bhangale, T.R., Criswell, L.A., Syvanen, A.C., Ronnblom, L., et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet., 7, 2011, e1002341.
99. [99] Diogo, D., Bastarache, L., Liao, K.P., Graham, R.R., Fulton, R.S., Greenberg, J.D., et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE, 10, 2015, e0122271.
100. [100] Kaiser, R., Criswell, L.A., Genetics research in systemic lupus erythematosus for clinicians: methodology, progress, and controversies. Curr. Opin. Rheumatol. 22 (2010), 119–125.
101. [101] Lee, Y.H., Choi, S.J., Ji, J.D., Song, G.G., Associations between PXK and TYK2 polymorphisms and systemic lupus erythematosus: a meta-analysis. Inflamm. Res. 61 (2012), 949–954.
102. [102] Mohan, C., Putterman, C., Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat. Rev. Nephrol. 11 (2015), 329–341.
103. [103] Nylander, A., Hafler, D.A., Multiple sclerosis. J. Clin. Invest. 122 (2012), 1180–1188.
104. [104] Ban, M., Goris, A., Lorentzen, A.R., Baker, A., Mihalova, T., Ingram, G., et al. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur. J. Hum. Genet. 17 (2009), 1309–1313.
105. [105] Dyment, D.A., Cader, M.Z., Chao, M.J., Lincoln, M.R., Morrison, K.M., Disanto, G., et al. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology 79 (2012), 406–411.
106. [106] Lopez-Isac, E., Campillo-Davo, D., Bossini-Castillo, L., Guerra, S.G., Assassi, S., Simeon, C.P., et al. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. Ann. Rheum. Dis., 2015, 10.1136/annrheumdis-2015-208154 pii: annrheumdis-2015-208154 (Epub ahead of print).
107. [107] Messemaker, T.C., Huizinga, T.W., Kurreeman, F., Immunogenetics of rheumatoid arthritis: understanding functional implications. J. Autoimmun., 2015, 10.1016/j.jaut.2015.07.007 pii: S0896-8411(15)30010-X (Epub ahead of print).
108. [108] de Lange, K.M., Barrett, J.C., Understanding inflammatory bowel disease via immunogenetics. J. Autoimmun., 2015, 10.1016/j.jaut.2015.07.013 pii: S0896-8411(15)30014-7 (Epub ahead of print).
109. [109] Ellinghaus, D., Ellinghaus, E., Nair, R.P., Stuart, P.E., Esko, T., Metspalu, A., et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 90 (2012), 636–647.
110. [110] Marroqui, L., Dos Santos, R.S., Floyel, T., Grieco, F.A., Santin, I., Op de Beeck, A., et al. TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and the innate immune response in human pancreatic beta-cells. Diabetes, 2015, 10.2337/db15-0362 pii: db150362 (Epub ahead of print).
111. [111] Wallace, C., Smyth, D.J., Maisuria-Armer, M., Walker, N.M., Todd, J.A., Clayton, D.G., The imprinted DLK1–MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat. Genet. 42 (2010), 68–71.
112. [112] Nagafuchi, S., Kamada-Hibio, Y., Hirakawa, K., Tsutsu, N., Minami, M., Okada, A., et al. TYK2 promoter variant and diabetes mellitus in the Japanese. EBioMedicine 2 (2015), 744–749.
113. [113] Liu, J.Z., Almarri, M.A., Gaffney, D.J., Mells, G.F., Jostins, L., Cordell, H.J., et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 44 (2012), 1137–1141.
114. [114] Jani, M., Massey, J., Wedderburn, L.R., Vencovsky, J., Danko, K., Lundberg, I.E., et al. Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. Ann. Rheum. Dis. 73 (2014), 1750–1752.
115. [115] Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005), 1054–1061.
116. [116] James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005), 1144–1148.
117. [117] Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005), 1779–1790.
118. [118] Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005), 387–397.
119. [119] Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S.B., Diaz, L.A., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
120. [120] Buchert, M., Burns, C.J., Ernst, M., Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene, 2015, 10.1038/onc.2015.150 (Epub ahead of print).
121. [121] Hanahan, D., Coussens, L.M., Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21 (2012), 309–322.
122. [122] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
123. [123] Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9 (2009), 798–809.
124. [124] Goldszmid, R.S., Dzutsev, A., Trinchieri, G., Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe 15 (2014), 295–305.
125. [125] Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
126. [126] Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr. Opin. Immunol. 27 (2014), 16–25.
127. [127] Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
128. [128] Simma, O., Zebedin, E., Neugebauer, N., Schellack, C., Pilz, A., Chang-Rodriguez, S., et al. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res. 69 (2009), 203–211.
129. [129] Stoiber, D., Kovacic, B., Schuster, C., Schellack, C., Karaghiosoff, M., Kreibich, R., et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J. Clin. Invest. 114 (2004), 1650–1658.
130. [130] Prchal-Murphy, M., Witalisz-Siepracka, A., Bednarik, K.T., Putz, E.M., Gotthardt, D., Meissl, K., et al. In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. Oncoimmunology, 4, 2015, e1047579.
131. [131] Zhang, Q., Sturgill, J.L., Kmieciak, M., Szczepanek, K., Derecka, M., Koebel, C., et al. The role of Tyk2 in regulation of breast cancer growth. J. Interferon Cytokine Res. 31 (2011), 671–677.
132. [132] Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15 (2015), 405–414.
133. [133] Zundler, S., Neurath, M.F., Interleukin-12: functional activities and implications for disease. Cytokine Growth Factor Rev. 26 (2015), 559–568.
134. [134] Colombo, M.P., Trinchieri, G., Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13 (2002), 155–168.
135. [135] Clevers, H., At the crossroads of inflammation and cancer. Cell 118 (2004), 671–674.
136. [136] Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
137. [137] Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
138. [138] Elinav, E., Nowarski, R., Thaiss, C.A., Hu, B., Jin, C., Flavell, R.A., Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer. 13 (2013), 759–771.
139. [139] Slattery, M.L., Lundgreen, A., The influence of the CHIEF pathway on colorectal cancer-specific mortality. PLoS ONE, 9, 2014, e116169.
140. [140] Slattery, M.L., Wolff, R.K., Lundgreen, A., A pathway approach to evaluating the association between the CHIEF pathway and risk of colorectal cancer. Carcinogenesis 36 (2015), 49–59.
141. [141] Maschler, S., Gebeshuber, C.A., Wiedemann, E.M., Alacakaptan, M., Schreiber, M., Custic, I., et al. Annexin A1 attenuates EMT and metastatic potential in breast cancer. EMBO Mol. Med. 2 (2010), 401–414.
142. [142] Overall, C.M., Lopez-Otin, C., Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2 (2002), 657–672.
143. [143] Vandenbroucke, R.E., Libert, C., Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nat. Rev. Drug Discov. 13 (2014), 904–927.
144. [144] Costantino, G., Egerbacher, M., Kolbe, T., Karaghiosoff, M., Strobl, B., Vogl, C., et al. Tyk2 and signal transducer and activator of transcription 1 contribute to intestinal I/R injury. Shock 29 (2008), 238–244.
145. [145] Schuster, C., Muller, M., Freissmuth, M., Sexl, V., Stoiber, D., Commentary on H. Ide et al., “Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells”. Biochem. Biophys. Res. Commun. 366 (2008), 869–870.
146. [146] Ide, H., Nakagawa, T., Terado, Y., Kamiyama, Y., Muto, S., Horie, S., Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem. Biophys. Res. Commun. 369 (2008), 292–296.
147. [147] Sang, Q.X., Man, Y.G., Sung, Y.M., Khamis, Z.I., Zhang, L., Lee, M.H., et al. Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis. Clin. Exp. Metastasis 29 (2012), 143–153.
148. [148] Smith, H.W., Marshall, C.J., Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11 (2010), 23–36.
149. [149] Kwaan, H.C., Mazar, A.P., McMahon, B.J., The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin. Thromb. Hemost. 39 (2013), 382–391.
150. [150] Dumler, I., Kopmann, A., Weis, A., Mayboroda, O.A., Wagner, K., Gulba, D.C., et al. Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999), 290–297.
151. [151] Dumler, I., Weis, A., Mayboroda, O.A., Maasch, C., Jerke, U., Haller, H., et al. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol. Chem. 273 (1998), 315–321.
152. [152] Kiian, I., Tkachuk, N., Haller, H., Dumler, I., Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb. Haemost. 89 (2003), 904–914.
153. [153] Kusch, A., Tkachuk, S., Haller, H., Dietz, R., Gulba, D.C., Lipp, M., et al. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. J. Biol. Chem. 275 (2000), 39466–39473.
154. [154] Patecki, M., von Schaewen, M., Tkachuk, S., Jerke, U., Dietz, R., Dumler, I., et al. Tyk2 mediates effects of urokinase on human vascular smooth muscle cell growth. Biochem. Biophys. Res. Commun. 359 (2007), 679–684.
155. [155] Shushakova, N., Tkachuk, N., Dangers, M., Tkachuk, S., Park, J.K., Hashimoto, K., et al. Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J. Cell Sci. 118 (2005), 2743–2753.
156. [156] McGettrick, A.F., O'Neill, L.A., How Metabolism Generates Signals during Innate Immunity and Inflammation. J. Biol. Chem. 288 (2013), 22893–22898.
157. [157] O'Neill, L.A., A broken krebs cycle in macrophages. Immunity 42 (2015), 393–394.
158. [158] Grunert, T., Leitner, N.R., Marchetti-Deschmann, M., Miller, I., Wallner, B., Radwan, M., et al. A comparative proteome analysis links tyrosine kinase 2 (Tyk2) to the regulation of cellular glucose and lipid metabolism in response to poly(I:C). J. Proteomics 74 (2011), 2866–2880.
159. [159] Derecka, M., Gornicka, A., Koralov, S.B., Szczepanek, K., Morgan, M., Raje, V., et al. Tyk2 and Stat3 regulate brown adipose tissue differentiation and obesity. Cell Metab. 16 (2012), 814–824.
160. [160] Blasco, M.A., Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 6 (2005), 611–622.
161. [161] Deng, Y., Chan, S.S., Chang, S., Telomere dysfunction and tumour suppression: the senescence connection. Nat. Rev. Cancer 8 (2008), 450–458.
162. [162] Yamada, O., Kawauchi, K., The role of the JAK–STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies. JAKSTAT, 2, 2013, e25256.
163. [163] Cheon, H., Borden, E.C., Stark, G.R., Interferons and their stimulated genes in the tumor microenvironment. Semin. Oncol. 41 (2014), 156–173.
164. [164] Kotredes, K.P., Gamero, A.M., Interferons as inducers of apoptosis in malignant cells. J. Interferon Cytokine Res. 33 (2013), 162–170.
165. [165] Bezu, L., Gomes-de-Silva, L.C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., et al. Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol., 6, 2015, 187.
166. [166] Gamero, A.M., Potla, R., Wegrzyn, J., Szelag, M., Edling, A.E., Shimoda, K., et al. Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J. Biol. Chem. 281 (2006), 16238–16244.
167. [167] Potla, R., Koeck, T., Wegrzyn, J., Cherukuri, S., Shimoda, K., Baker, D.P., et al. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol. Cell Biol. 26 (2006), 8562–8571.
168. [168] Shimoda, H.K., Shide, K., Kameda, T., Matsunaga, T., Shimoda, K., Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions. Biochem. Biophys. Res. Commun. 400 (2010), 252–257.
169. [169] Shimoda, K., Kamesaki, K., Numata, A., Aoki, K., Matsuda, T., Oritani, K., et al. Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. J. Immunol. 169 (2002), 4707–4711.
170. [170] Wan, J., Fu, A.K., Ip, F.C., Ng, H.K., Hugon, J., Page, G., et al. Tyk2/STAT3 signaling mediates beta-amyloid-induced neuronal cell death: implications in Alzheimer's disease. J. Neurosci. 30 (2010), 6873–6881.
171. [171] Rani, M.R., Pandalai, S., Shrock, J., Almasan, A., Ransohoff, R.M., Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta. J. Interferon Cytokine Res. 27 (2007), 767–779.
172. [172] Carmo, C.R., Lyons-Lewis, J., Seckl, M.J., Costa-Pereira, A.P., A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells. PLoS ONE, 6, 2011, e19861.
173. [173] Schmeisser, H., Bekisz, J., Zoon, K.C., New function of type I IFN: induction of autophagy. J. Interferon Cytokine Res. 34 (2014), 71–78.
174. [174] Dong, G., You, M., Fan, H., Ding, L., Sun, L., Hou, Y., STS-1 promotes IFN-alpha-induced autophagy by activating the JAK1–STAT1 signaling pathway in B cells. Eur. J. Immunol. 45 (2015), 2377–2388.
175. [175] Negrini, S., Gorgoulis, V.G., Halazonetis, T.D., Genomic instability – an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11 (2010), 220–228.
176. [176] Helleday, T., Eshtad, S., Nik-Zainal, S., Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15 (2014), 585–598.
177. [177] Biggar, K.K., Li, S.S., Non-histone protein methylation as a regulator of cellular signalling and function. Nat. Rev. Mol. Cell Biol. 16 (2015), 5–17.
178. [178] Yu, Q., Katlinskaya, Y.V., Carbone, C.J., Zhao, B., Katlinski, K.V., Zheng, H., et al. DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep. 11 (2015), 785–797.
179. [179] Hartlova, A., Erttmann, S.F., Raffi, F.A., Schmalz, A.M., Resch, U., Anugula, S., et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 42 (2015), 332–343.
180. [180] Adam, L., Bandyopadhyay, D., Kumar, R., Interferon-alpha signaling promotes nucleus-to-cytoplasmic redistribution of p95Vav, and formation of a multisubunit complex involving Vav, Ku80, and Tyk2. Biochem. Biophys. Res. Commun. 267 (2000), 692–696.
181. [181] Fell, V.L., Schild-Poulter, C., The Ku heterodimer: function in DNA repair and beyond. Mutat. Res. Rev. Mutat. Res. 763 (2015), 15–29.
182. [182] Shi, S., Larson, K., Guo, D., Lim, S.J., Dutta, P., Yan, S.J., et al. Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability. Nat. Cell Biol. 10 (2008), 489–496.
183. [183] Silver-Morse, L., Li, W.X., JAK–STAT in heterochromatin and genome stability. JAKSTAT, 2, 2013, e26090.
184. [184] Santos, J., Mesquita, D., Barros-Silva, J.D., Jeronimo, C., Henrique, R., Morais, A., et al. Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements. Oncoscience 2 (2015), 497–507.
185. [185] Song, X.C., Fu, G., Yang, X., Jiang, Z., Wang, Y., Zhou, G.W., Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining. Mol. Cell Proteomics 7 (2008), 163–169.
186. [186] Zhu, X., Lv, J., Yu, L., Zhu, X., Wu, J., Zou, S., et al. Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol. Oncol. 112 (2009), 248–256.
187. [187] Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res., 43, 2015 D805-11.
188. [188] Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res., 39, 2011 D945-50.
189. [189] Lee, S., Park, H.Y., Kang, S.Y., Kim, S.J., Hwang, J., Lee, S., et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget 6 (2015), 17764–17776.
190. [190] Kaminker, J.S., Zhang, Y., Waugh, A., Haverty, P.M., Peters, B., Sebisanovic, D., et al. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res. 67 (2007), 465–473.
191. [191] Tomasson, M.H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111 (2008), 4797–4808.
192. [192] Ruhe, J.E., Streit, S., Hart, S., Wong, C.H., Specht, K., Knyazev, P., et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 67 (2007), 11368–11376.
193. [193] Sanda, T., Tyner, J.W., Gutierrez, A., Ngo, V.N., Glover, J., Chang, B.H., et al. TYK2–STAT1–BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 3 (2013), 564–577.
194. [194] Crescenzo, R., Abate, F., Lasorsa, E., Tabbo, F., Gaudiano, M., Chiesa, N., et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27 (2015), 516–532.
195. [195] Roberts, K.G., Li, Y., Payne-Turner, D., Harvey, R.C., Yang, Y.L., Pei, D., et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371 (2014), 1005–1015.
196. [196] Velusamy, T., Kiel, M.J., Sahasrabuddhe, A.A., Rolland, D., Dixon, C.A., Bailey, N.G., et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 124 (2014), 3768–3771.
197. [197] Sohn, S.J., Barrett, K., Van Abbema, A., Chang, C., Kohli, P.B., Kanda, H., et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J. Immunol. 191 (2013), 2205–2216.
198. [198] Tokarski, J.S., Zupa-Fernandez, A., Tredup, J.A., Pike, K., Chang, C., Xie, D., et al. Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. J. Biol. Chem. 290 (2015), 11061–11074.
199. [199] Li, Z., Gakovic, M., Ragimbeau, J., Eloranta, M.L., Ronnblom, L., Michel, F., et al. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. J. Immunol. 190 (2013), 2335–2344.
200. [200] Staerk, J., Kallin, A., Demoulin, J.B., Vainchenker, W., Constantinescu, S.N., JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J. Biol. Chem. 280 (2005), 41893–41899.
201. [201] Yeh, T.C., Dondi, E., Uze, G., Pellegrini, S., A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc. Natl. Acad. Sci. USA 97 (2000), 8991–8996.
202. [202] Gauzzi, M.C., Velazquez, L., McKendry, R., Mogensen, K.E., Fellous, M., Pellegrini, S., Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J. Biol. Chem. 271 (1996), 20494–20500.